A Study to Test How Healthy Men Tolerate Different Doses of BI 1595043
- First Posted Date
- 2021-03-09
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT04789304
- Locations
- ๐ง๐ช
SGS Life Science Services - Clinical Research, Edegem, Belgium
A Study in Healthy Men to Find Out How BI 1015550 is Taken up and Handled by the Body
- Conditions
- Healthy
- Interventions
- Drug: BI 1015550 (C-14)
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 6
- Registration Number
- NCT04771286
- Locations
- ๐ณ๐ฑ
PRA Health Sciences Onderzoekscentrum Martini, Groningen, Netherlands
A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)
- Conditions
- Non-alcoholic Steatohepatitis (NASH)
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 295
- Registration Number
- NCT04771273
- Locations
- ๐บ๐ธ
North Alabama Health Research, LLC, Huntsville, Alabama, United States
๐บ๐ธSouthern California Research Center, Coronado, California, United States
๐บ๐ธVelocity Clinical Research, Panorama City, California, United States
A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Drug: Spesolimab- solution for injectionDrug: Placebo matching to spesolimab- solution for injection
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 52
- Registration Number
- NCT04762277
- Locations
- ๐บ๐ธ
Dermatology Research Associates, Los Angeles, California, United States
๐บ๐ธDawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States
๐บ๐ธUniversity of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface
- Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 67
- Registration Number
- NCT04752215
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center Orlando, Orlando, Florida, United States
๐บ๐ธUniversity of Alabama at Birmingham, Birmingham, Alabama, United States
๐บ๐ธValkyrie Clinical Trials, Los Angeles, California, United States
A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease
- Conditions
- Diabetic Nephropathies
- Interventions
- Drug: Placebo matching BI 685509
- First Posted Date
- 2021-02-11
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 243
- Registration Number
- NCT04750577
- Locations
- ๐ญ๐ฐ
Prince of Wales Hospital, Hong Kong, Hong Kong
๐ญ๐ฐTung Wah Hospital, Hong Kong, Hong Kong
๐ฒ๐พUniversiti Sains Malaysia Hospital, Kelantan, Malaysia
Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.
- Conditions
- Non-squamous, Non-Small Cell Lung Cancer
- Interventions
- Drug: other systemic therapy
- First Posted Date
- 2021-02-11
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 110
- Registration Number
- NCT04750824
- Locations
- ๐บ๐ธ
Cardinal Health, Dublin, Ohio, United States
A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive)
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 15
- Registration Number
- NCT04742556
- Locations
- ๐ฏ๐ต
National Cancer Center Hospital, Tokyo, Chuo-ku, Japan
๐ฏ๐ตJapanese Foundation for Cancer Research, Tokyo, Koto-ku, Japan
๐ฏ๐ตNational Cancer Center Hospital East, Chiba, Kashiwa, Japan
An Expanded Access Program in Belgium to Provide Nintedanib to People With Lung Diseases Called Non-IPF ILDs Who Have no Alternative Treatment Options
- Conditions
- Lung Diseases, Interstitial
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2022-09-09
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT04739150
- Locations
- ๐ง๐ช
Aalst - HOSP Onze-Lieve-Vrouw, Aalst, Belgium
๐ง๐ชULB Hopital Erasme, Anderlecht, Belgium
๐ง๐ชZiekenhuis Netwerk Antwerpen (ZNA) - Campus Middelheim, Antwerpen, Belgium
A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 261
- Registration Number
- NCT04736628
- Locations
- ๐บ๐ธ
Research by Design, LLC, Chicago, Illinois, United States
๐บ๐ธHomestead Associates in Research, Miami, Florida, United States
๐บ๐ธNevada Kidney Disease and Hypertension Centers, PLLC, Las Vegas, Nevada, United States